May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Longitudinal Nationwide Antimicrobial Susceptibility Surveillance in Ocular Isolates: Results From Ocular TRUST 2
Author Affiliations & Notes
  • P. A. Asbell
    Ophthalmology, Mount Sinai School of Medicine, New York, New York
  • D. F. Sahm
    Ophthalmology, Eurofins Medinet, Inc., Anti-Infective Services, Herndon, Virginia
  • Ocular TRUST
    Ophthalmology, Mount Sinai School of Medicine, New York, New York
  • Footnotes
    Commercial Relationships  P.A. Asbell, Inspire Pharmaceuticals; Vistakon Pharmaceuticals, C; lecture fees from Alcon Laboratories, Allergan Pharmaceuticals, Santen Pharmaceutical, Inspire Pharmaceuticals, and Vistakon Pharmaceuticals., R; D.F. Sahm, Eurofins Medinet, Inc., Anti-Infective Services, E; Vistakon Pharmaceuticals, C; Vistakon Pharmaceuticals, R.
  • Footnotes
    Support  Vistakon Pharmaceuticals, LLC
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1986. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. A. Asbell, D. F. Sahm, Ocular TRUST; Longitudinal Nationwide Antimicrobial Susceptibility Surveillance in Ocular Isolates: Results From Ocular TRUST 2. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1986. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Ocular TRUST (Tracking Resistance in the US Today) is the only nationwide antimicrobial susceptibility surveillance program in isolates from ocular infections. Data from the second annual report from this ongoing program (Ocular TRUST 2) are presented.

Methods: : Geographically distributed eye centers and community hospitals submitted samples from eye infections treated between October 2006 and June 2007. Isolates were tested by broth microdilution according to CLSI methodology at a centralized independent laboratory. The antimicrobial panel included azithromycin (AZTH), oxacillin, penicillin, polymyxin B, tobramycin, trimethoprim, and four fluoroquinolones (FQs): levofloxacin (LEV), ciprofloxacin (CIP), gatifloxacin (GAT), and moxifloxacin (MOX). MICs were interpreted as susceptible, intermediate, or resistant according to 2007 CLSI criteria. Oxacillin resistance was used as a marker for methicillin resistance and susceptibility in Staphylococcus aureus (MRSA, MSSA) and S. epidermidis (MRSE, MSSE).

Results: : Ocular isolates: S. aureus (N=151;MRSA, n=83; MSSA, n=68); S. epidermidis (N=51; MRSE,n=31; MSSE, n=20); Streptococcus pneumoniae(N=188). Staphylococci susceptibilities toLEV, GAT, and MOX were identical,regardless of species or methicillin status(MRSA, 18%; MSSA, 93%; MRSE, 32%; MSSE,90%). Macrolide (AZTH) susceptibility:MRSA, 8%; MSSA, 62%; MRSE, 13%; MSSE, 40%.MRSA most susceptible to trimethoprim (95%). All S. pneumoniae isolates were susceptible toLEV, GAT, and MOX; 69% were susceptible toAZTH.

Conclusions: : Nationwide susceptibility patterns of staphylococci and S. pneumoniae are identical for LEV, GAT, and MOX. Macrolide susceptibility (as represented by AZTH) was lower than FQs for ocular pathogens tested.

Keywords: bacterial disease • ocular irritancy/toxicity testing • antibiotics/antifungals/antiparasitics 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×